Ca-AKG for bone health: the postmenopausal osteopenia evidence

Ca-AKG has one randomized human bone trial, plus a growing preclinical literature on osteoblasts, osteoclasts and age-related bone loss. That gives it more bone-specific evidence than many longevity supplements—but it still has not been shown to prevent fractures or treat osteoporosis in humans.

The key human result is a reduction in CTX, a bone-resorption marker, in postmenopausal women with osteopenia. The newer animal and cell studies help explain why that result is biologically plausible.

The human trial: what was actually tested?

In 2007, 76 postmenopausal women aged 45–65 with osteopenia were randomized in a double-blind six-month trial [1].

The intervention provided 6 g/day of AKG as the calcium salt, supplying 1.68 g/day of calcium, taken as chewable tablets three times daily with meals. The control group received the same calcium amount as calcium carbonate.

This is an important design detail: calcium exposure was matched. The between-group difference therefore points toward an AKG contribution rather than simply “more calcium.”

What happened to CTX?

Serum CTX fell 37% from baseline in the AKG-calcium group at 24 weeks, while the calcium-only group did not show a significant change. Between-group differences were significant at both 12 and 24 weeks [1].

CTX reflects bone resorption—the breakdown side of bone turnover. A lower CTX suggests less active bone resorption.

That is a meaningful pharmacodynamic result. It is not the same as proving fewer fractures.

Did Ca-AKG increase bone density?

Not convincingly in this trial.

Lumbar-spine bone mineral density increased 1.6% from baseline in the AKG-calcium group, but the between-group difference versus calcium alone was only 0.9% and was not statistically significant.

The trial lasted only six months, and the BMD difference was within the approximate measurement variability of DEXA. So the study cannot establish a clinically meaningful bone-density benefit.

No fracture-prevention claim can be made either: the study was far too small and short to test that outcome.

The dose question is more subtle than “six times higher”

The trial used 6 g/day of the AKG-calcium intervention, not a simple 6 g dose of pure AKG base. Modern supplement labels also vary in whether they declare Ca-AKG salt mass or AKG base mass.

That makes direct “six-fold dose” comparisons less clean than they first appear.

The practical conclusion is still valid: the randomized bone trial used a substantially larger Ca-AKG exposure than the ~0.8–1 g/day labeled doses common in longevity products. We do not have a human bone trial showing that 1 g/day reproduces the CTX effect.

See Ca-AKG dosage for the salt-mass versus AKG-base issue.

Age-related osteoporosis: Wang 2020

A 2020 preclinical study found that AKG increased bone mass and attenuated age-related bone loss in aged rodent models [2].

AKG also improved osteogenic and regenerative behavior in aged bone-marrow mesenchymal stem cells. The proposed mechanism involved epigenetic changes, including lower H3K9me3 and H3K27me3 and downstream effects on BMP/Nanog signaling.

This provides a bone-aging mechanism that is independent of the 2007 human CTX trial, but it remains animal and cell evidence.

AKG appears to act on both sides of bone remodeling

Bone remodeling depends on two opposing cell types:

• osteoclasts, which resorb bone;
• osteoblasts, which build bone.

Several mechanistic studies suggest AKG can influence both.

A 2021 study found that AKG inhibited osteoclast differentiation and reduced ROS signaling, with epigenetic regulation at the Slc7a11 promoter contributing to the effect [3].

A 2023 study likewise found that raising intracellular AKG inhibited RANKL-induced osteoclastogenesis through a PHD1-dependent mechanism involving NF-κB signaling [4].

On the formation side, a 2019 osteoblast-cell study found that AKG increased differentiation and mineralization markers through JNK and mTOR/S6K1/S6 signaling [5].

Together, these studies support a plausible “less resorption + more osteogenic activity” model. None is a human oral Ca-AKG outcome trial.

What does the 2026 tendon-to-bone study add?

A 2026 study used ovariectomized rats—an established model of postmenopausal bone loss—and tested AKG during rotator-cuff tendon-to-bone repair [6].

AKG-treated animals had better local bone microarchitecture, more osteoblastic and less osteoclastic activity, and stronger repaired tendon-to-bone interfaces.

But there is a major translational limitation: AKG was delivered locally in an enriched fibrin gel at the surgical site, not orally as a supplement. This paper cannot be used to claim that Ca-AKG capsules improve rotator-cuff healing in people.

Is Ca-AKG proven for osteoporosis?

No.

The only randomized human bone trial enrolled women with osteopenia, not established osteoporosis. It showed a change in a bone-turnover biomarker, not fracture prevention.

The preclinical literature makes AKG a credible research candidate for age-related bone biology, but it is not an evidence-based substitute for osteoporosis diagnosis and treatment.

Who does the human evidence apply to?

Direct human bone evidence currently applies to postmenopausal women with osteopenia.

There is no comparable randomized Ca-AKG bone trial in men, premenopausal women, healthy young adults or patients with established osteoporosis.

Safety at the bone-trial dose

The 2007 trial reported similar overall dropout rates between groups, but mild dyspepsia occurred more often with Ca-AKG—six cases versus one in the calcium-only group [1].

The trial's calcium exposure was also substantial. Anyone contemplating unusually high Ca-AKG doses should account for total calcium intake and individual kidney/mineral-metabolism factors rather than trying to copy the trial independently.

See Ca-AKG side effects and safety.

Bottom line

Ca-AKG has a genuine human bone signal: a randomized six-month trial found a larger reduction in CTX than calcium alone in postmenopausal women with osteopenia.

Newer preclinical work adds coherent mechanisms involving aged bone stem cells, osteoclast suppression, osteoblast differentiation and postmenopausal-type bone repair.

But the evidence stops short of the claims that matter most clinically. Ca-AKG has not been shown to prevent fractures, treat osteoporosis or produce a meaningful BMD gain in a randomized human trial.

For the full Ca-AKG evidence hierarchy, return to the Ca-AKG pillar.